A Study Evaluates the Safety, Pharmacokinetics, Immunogenicity and Efficacy of QLS31903 in Advanced Solid Tumor Patients

Clinical trial NCT05823285 · RECRUITING

Trial details

NCT number: NCT05823285
Sponsor: Qilu Pharmaceutical Co., Ltd.
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Advanced Solid Tumors

Start date: 2023-03-22
Primary completion: 2025-06-15
Enrollment: 150

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.